(Press-News.org) CHICAGO — A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. The findings were part of the results of a Phase III clinical trial presented today at the 2014 American Society of Clinical Oncology Annual Meeting by the study's primary author Jan Buckner, M.D., deputy director, Cancer Practice, at Mayo Clinic Cancer Center.
"On average, patients who received PCV lived 5.5 years longer than those who received radiation alone," says Dr. Buckner. "These findings build on results published in the Journal of Clinical Oncology in 2012 which showed that PCV given with radiation therapy at the time of initial diagnosis prolongs progression free-survival but not overall survival."
The trial, RTOG 9802, enrolled 251 patients with low-grade gliomas between October 1998 and June 2002 to address the role of chemotherapy following radiation treatment. Patients enrolled were at high risk compared to other low-grade glioma patients because they were 40 years of age or older or had a less than complete surgical removal of their tumor if they were under 40.
Investigators also found that patients with oligodendroglioma had better outcomes than those with astrocytoma or oligoastrocytoma, as did females.
"RTOG 9802 involved a network of investigators across the United States and Canada working through the National Cancer Institute's National Clinical Trials Network," says Dr. Buckner. "This trial could only have been conducted through a publicly-funded national clinical trials network." He says the next step is to study tumor tissue from participating patients to identify biomarkers that will allow researchers to determine which patients will benefit the most from specific therapies.
According to the American Cancer Society, approximately 23,000 people will be diagnosed with primary brain tumors in the United States in 2014 and, of those, 10 to 15 percent will have low-grade gliomas. Gliomas are tumors that begin in the brain or spinal cord. They are the most common form of primary brain tumor.
INFORMATION:
Funding for the trial was provided by the National Cancer Institute, and the trial was conducted by investigators at institutions participating in the Radiation Treatment Oncology Group, the Alliance for Clinical Trials in Oncology, the Eastern Cooperative Oncology Group and the Southwest Oncology Group.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit 150years.mayoclinic.org, http://www.mayoclinic.org/ and newsnetwork.mayoclinic.org.
MEDIA CONTACT:
Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu
Chemotherapy following radiation treatment improves progression-free survival
2014-06-01
ELSE PRESS RELEASES FROM THIS DATE:
New report estimates nearly 19 million cancer survivors in the US by 2024
2014-06-01
ATLANTA – June 1, 2014 – The number of cancer survivors in the United States, currently estimated to be 14.5 million, will grow to almost 19 million by 2024, according to an updated report by the American Cancer Society. The second edition of Cancer Treatment & Survivorship Facts & Figures, 2014-2015 and an accompanying journal article published in CA: A Cancer Journal for Clinicians find that even though cancer incidence rates have been decreasing for ten years, the number of cancer survivors is growing. This is the result of increases in cancer diagnoses driven by the ...
Reducing emissions will be the primary way to fight climate change, UCLA-led study finds
2014-06-01
Forget about positioning giant mirrors in space to reduce the amount of sunlight being trapped in the earth's atmosphere or seeding clouds to reduce the amount of light entering earth's atmosphere. Those approaches to climate engineering aren't likely to be effective or practical in slowing global warming.
A new report by professors from UCLA and five other universities concludes that there's no way around it: We have to cut down the amount of carbon being released into the atmosphere. The interdisciplinary team looked at a range of possible approaches to dissipating ...
ALTTO test of dual HER2 blockade finds single agent remains the gold standard
2014-06-01
CHICAGO — June 1, 2014 — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).
MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network.
Results of the phase III clinical trial, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study), demonstrated that adding ...
The ethics of knowing where to stop treatment in a sick and elderly patient
2014-06-01
An Emeritus Professor of medical ethics at Imperial College London will deliver a presentation at this year's Euroanaesthesia meeting titled 'Escalating care for the comorbid elderly-where do we stop?". Raanan Gillon, who is President of the UK's Institute of Medical Ethics, will argue that a patient's age should not in itself be considered an ethically relevant criterion for deciding 'where to stop'.
Acknowledging that there is a morally plausible counter-argument – known in the UK as 'the fair innings argument'- according to which scarce life prolonging resources should ...
Study of 55 million people adds further evidence that patients admitted to hospital at weekends have higher mortality
2014-06-01
A systematic review and meta-analysis of hospital data worldwide, presented as this year's Euroanaesthesia meeting in Stockholm, adds further evidence that patients admitted to hospital at weekends have higher mortality than those admitted on weekdays. The study is by Dr Hiroshi Hoshijima, Tohoku University, Sendai, Japan, and colleagues.
The analysis included 72 studies from various world regions, covering 55,053,719 participants. The authors found that weekend admission was associated with increased morality of between 15% and 17% depending on the statistical technique ...
Risk of death highest following surgery in afternoons, at weekends, and in February
2014-06-01
New research presented at this year's Euroanaesthesia show that on weekends, in the afternoons and in February are the times when the risk of death following surgery is the highest. The research is by Dr Felix Kork and Professor Claudia Spies, Charité - University Medicine Berlin, Germany and colleagues.
Hospital mortality is subject to day-night, weekly and seasonal variability. This has been shown for various populations, settings, and in different regions of the world. However, a cyclic influence on hospital mortality has not been shown in patients after surgery. ...
Poor coverage of specific gene sets in exome sequencing gives cause for concern
2014-06-01
With services based on exome sequencing becoming affordable to patients at a reasonable price, the question of the quality of the results provided has become increasingly important. The exome is the DNA sequence of genes that are translated into protein. These protein-coding regions contain most of the currently-known disease-causing genetic mutations. The American College of Medical Genetics and Genomics (ACMG) has recommended the reporting to patients of clinically actionable incidental genetic findings in the course of clinical exome testing. Specifically, mutations ...
Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease
2014-05-31
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, and subsequently was granted regular approval in 2013. The drug also has shown dramatic responses in ...
Results in Phase I trial of OMP-54F28, a Wnt inhibitor targeting cancer stem cells
2014-05-31
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials are now open for OMP-54F28 (FZD8-Fc) in combinations with standard therapy for pancreatic, ovarian and liver cancers, ...
ASCO: One step closer to a breath test for lung cancer
2014-05-31
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
"This could totally revolutionize lung cancer screening and diagnosis. The perspective here is the development of a non-traumatic, easy, cheap approach to early detection and differentiation of lung cancer," ...